Turning Point Therapeutics
- Pharmaceutical Preparations
- San Diego, California
Compensation history
Top executives at Turning Point Therapeutics received an average of $6M per person in annual compensation from 2019 to 2021.
Average pay of disclosed executives at Turning Point Therapeutics
By year
- 2021
AC$17MAthena CountouriotisPresident and Chief Executive OfficerMH$6MMohammad HirmandChief Medical OfficerAN$6MAnnette NorthFormer Executive Vice President and General CounselPT$5MPaolo TombesiExecutive Vice President and Chief Financial OfficerSP$4MSiegfried Reich, P.H.DExecutive Vice President and Chief Scientific OfficerYL$4MYi LarsonFormer Executive Vice President and Chief Financial OfficerBB$2MBrian BakerFormer Senior Vice President, Finance and Administration- 2020
AC$15MAthena CountouriotisPresident and Chief Executive OfficerSP$6MSiegfried Reich, P.H.DExecutive Vice President and Chief Scientific OfficerAN$3MAnnette NorthFormer Executive Vice President and General CounselYL$2MYi LarsonFormer Executive Vice President and Chief Financial OfficerMH$690KMohammad HirmandChief Medical Officer
Executives
We found seven executives who work or worked at Turning Point Therapeutics.
Paolo Tombesi
Turning Point Therapeutics
Chief Financial Officer
Mohammad Hirmand
Turning Point Therapeutics
Chief Medical Officer
Siegfried PHD
Turning Point Therapeutics
Chief Scientific Officer
Annette North
Turning Point Therapeutics
General Counsel
Yi Larson
Turning Point Therapeutics
Chief Financial Officer
Brian Baker
Turning Point Therapeutics
Former Senior Vice President, Finance and Administration
Athena Countouriotis
Turning Point Therapeutics
Chief Executive Officer
News
About Turning Point Therapeutics
- Industry classifications
- DivisionManufacturing
- Major groupChemicals And Allied Products
- Industry groupDrugs
- IndustryPharmaceutical Preparations
- Address10628 Science Center Drive, Suite 200, San Diego, California 92121
- Phone858-926-5251
- Fiscal year endDecember 31
- Former names
- TP Therapeutics, Inc.Until October 29, 2018
- TP Therapeutics, INCUntil May 24, 2017
Source: SEC filing on April 29, 2022.